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Objectives—We aimed to evaluate the relation between menstrual and reproductive factors, 
exogenous hormones, and risk of pancreatic cancer (PC).
Methods—Eleven case-control studies within the International Pancreatic Cancer Case-Control 
Consortium (PanC4) took part in the present study, including in total 2,838 case and 4,748 control 
women. Pooled estimates of odds ratios (ORs) and their 95% confidence intervals (CIs) were 
calculated using a two-step logistic regression model and adjusting for relevant covariates.
Results—An inverse OR was observed in women who reported having had hysterectomy 
(ORyesvs.no 0.78, 95%CI 0.67–0.91), remaining significant in post-menopausal women and never-
smoking women, adjusted for potential PC confounders. A mutually-adjusted model with the joint 
effect for hormone replace therapy (HRT) and hysterectomy showed significant inverse 
associations with PC in women who reported having had hysterectomy with HRT use (OR 0.64, 
95%CI 0.48–0.84).
Conclusion—Our large pooled analysis suggests that women who have had a hysterectomy may 
have reduced risk of PC. However, we cannot rule out that the reduced risk could be due to factors 
or indications for having had a hysterectomy. Further investigation of risk according to HRT use 
and reason for hysterectomy may be necessary.
Keywords
Pancreatic cancer; menstrual and reproductive factors; exogenous hormones; hysterectomy; 
consortium
INTRODUCTION
Pancreatic cancer is the twelfth most common cancer in the world1, but has among the 
poorest survival of all cancers. The aggressive nature of the disease and the lack of early 
markers or effective treatment options results in the lowest 5-year survival rate (3–7%) of all 
cancers in the US2,3. About 95% of pancreatic cancers are ductal adenocarcinomas (PC). 
Tobacco smoking is the main risk factor for PC and explains about 20% of the risk in a 
population where prevalence of smoking is 30%4,5. ABO non-O blood group, obesity, long-
term type 2 diabetes, family history of PC, histories of pancreatitis and possibly heavy 
alcohol consumption, familial rare inherited mutations in BRCA2, p16 and other genes, and 
common variants in at least eight genetic loci are other known PC risk factors6–8.
PC incidence is somewhat higher in men than in women. In the US, between 2007 and 2011, 
the sex ratio ranged from 1.3 (for ages 40–44), to 1.1 (for ages 85 and over)9. In Europe, the 
estimated sex ratio in 2012 is highest at 1.9, for ages 40–44, and is 1.1 at ages 75 and over10. 
Some studies, using castrated rats, showed that administration of sex steroids inhibits the 
development and growth of preneoplastic lesions of the pancreas11,12. Motivated by these 
observations, and under the hypothesis that greater exposure to female sex hormones 
(through early menarche, later menopause, high number of pregnancies, and having a history 
of hormone use) decreases the risk of PC, several epidemiological studies have examined 
possible risk associations with menstrual and reproductive factors, and hormone use, but 
with inconsistent results. A review paper on reproductive factors and PC13, two meta-
analyses on parity14,15, and a recent meta-analysis16 attempted to make clear the relations 
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between these factors and PC risk. Comparing and summarizing previous evidence, 
however, is not a simple task. Inconsistencies in results may arise from different 
categorization and reference categories of exposure variables, different adjustment or 
confounding variables, and various study designs and target populations. Further, many of 
the previous studies were limited by small numbers of cases, and some were limited by 
inadequate adjustment for smoking, the primary risk factor for pancreatic cancer.
The aim of the present study was to assess whether or not menstrual or reproductive factors 
or hormone use are associated with risk of developing PC. Pooled individual analyses of 
eleven case-control studies in the PanC4 consortium allowed us to obtain precise estimates 
of risks and to analyze the associations in detail.
MATERIALS AND METHODS
Studies
Eleven case-control studies with information on menstrual and reproductive factors and 
hormone use were available within the PanC4 consortium17–26. At a minimum, the studies 
were able to provide information on age at menarche and age at menopause. The total 
number of women available in the combined data set were 2,838 with pancreatic cancer and 
4,748 controls. The Surveillance of Environmental Aspects Related to Cancer in Humans 
(SEARCH), Toronto and Shanghai-I studies included proxy responders, accounting for 
14.5% of the case and 4.4% of the control women (Table 1).
Exposure variables
Questions about menstrual and reproductive factors and exogenous hormone were generally 
similar across all the studies; however, full harmonization of the data was performed with 
the collaboration of the study investigators. Variables included in the analysis were: reported 
age at menarche, age at menopause, type of menopause (natural or surgical), history of 
oophorectomy, hysterectomy, age at hysterectomy, number of pregnancies, number of births 
(including live and stillbirths), age at first birth, number of abortions (including induced and 
spontaneous), history of oral contraceptive (OC) use, duration of OC use, use of menopause 
hormone replacement therapy (HRT), and duration of HRT. We also calculated the 
cumulative lifetime number of menstrual cycles, by adapting the index proposed by Chavez-
MacGregor27 as follow: for postmenopausal women, we calculated the difference between 
age at menopause and age at menarche; for each birth and stillbirth we subtracted cycles 
during 36 weeks, and 12 weeks for each abortion. Menstrual cycles absent while under OC 
use were assumed to last 28 days duration. For pre or perimenopausal women, we used age 
at recruitment instead of age at menopause. Missing age at menopause was imputed using 
the study-specific mean age at menopause or in case of both ovaries removed, the age at 
surgery.
Statistical analysis
Two-stage models were used to estimate pooled odds ratios (OR) between menstrual and 
reproductive factors, hormone use and PC risk. At the first stage, for each study, the 
association between each factor and PC risk was assessed by estimating the OR and 95% 
Lujan-Barroso et al. Page 4













confidence interval (CI) using study-specific logistic regression models28. All models in the 
first step were adjusted by age (<45, 45–49,50–54, 55–59, 60–64, 65–69, 70–75, ≥75 years), 
education (≤ 8th grade, 9th-11th grade, 12th grade or high school graduates, some college or 
college graduate, ≥1 year of graduate school), usual body mass index (BMI, <20, 20 to <25, 
25 to <30, ≥30 kg/m2), history of non-gestational diabetes mellitus, cigarette smoking 
(never-smokers, current smokers < 20 cigarettes/day, current smokers ≥20 cigarettes/day, ex-
smokers < 10 years, ex-smokers ≥10 years), alcohol (no info available, 0 to <1 drink/day, 1 
to < 4 drinks/day, ≥4 drinks/day), race (Non-Hispanic white, non-Hispanic black, Hispanic, 
Asian/Pacific Islander, American Indian/Alaskan native) and center (for multicentric 
studies). History of pancreatitis was not included as an adjustment covariate in the present 
analysis because some of the studies observed no controls with this exposure. To account for 
possible differences in hormone levels during pregnancies, number of pregnancies was 
included when lifetime cumulative cycles was evaluated. At the second stage, pooled effect 
estimates across studies were calculated using random effects meta-analysis29. To evaluate 
study-based heterogeneity, we calculated the χ2 statistic and the index I-square30. Galbraith 
plots were used to examine sources of heterogeneity31, and sensitivity analyses excluding 
the study/studies identified with Galbraith plots were performed to evaluate study influence 
on pooled ORs. Studies that contributed significantly to heterogeneity in the pooled 
estimates for reproductive factors were excluded from the analysis of that factor. In order to 
account for all sources of hormone exposure at the same time, mutually adjusted models 
were evaluated after possible collinearity between exposure variables was assessed. Effect-
measure modification by tobacco use (never, current, former), BMI (under+normal weight 
vs. obese+overweight), and histories of diabetes were evaluated using the likelihood-ratio 
statistic. All analyses were additionally examined restricted to postmenopausal women and 
to never smokers. Finally, sensitivity analyses excluding the proxy respondents and 
stratifying by source of control participants (population- or hospital-based) from the 
mutually adjusted models were also performed.
RESULTS
Table 1 gives study characteristics and distributions of the core variables according to PC 
status. Case subjects were older than controls, reported higher BMIs, and were more likely 
to be current or ex-smokers. Greater proportions of women who had had diabetes or 
pancreatitis were observed among cases than in controls.
To account for possible differences in the exposure variables by race/ethnicity, distributions 
were evaluated and only minor differences in age at menarche were observed between Asian 
and non-Asian ethnicities; however these differences were not statistically significant (data 
not shown).
All models of menstrual and reproductive factors and hormone use variables were adjusted 
for attained age, education, race, usual BMI, cigarette smoking, histories of diabetes and use 
of alcohol, and center. A statistically significant inverse association was observed in women 
who reported having had hysterectomy (OR 0.78, 95%CI 0.67–0.91), remaining consistent 
in postmenopausal and never-smoking women (Table 2). Earlier hysterectomy (≤41 years) 
showed non-significant inverse associations with PC risk (OR≤37vs>52 0.87; 0.53–1.42; 
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OR>37&≤41vs>52 0.62; 0.37–1.05) (Table 2). The observed OR for HRT users was 0.82 
(95%CI 0.68–0.98) (Table 2).
Non-significant ORs below unity were observed in women who had later menarche 
(OR>14vs<12 0.85, 95%CI 0.66–1.08), bilateral oophorectomy (OR 0.83, 95%CI 0.64–1.06), 
used OC (OR 0.83, 95%CI 0.69–1.01), reported long-term use of HRT (OR≥36vsnon-users 
0.81, 95%CI 0.66–1.00) or had high number of menstrual cycles (OR>455vs≤333 0.74, 95%CI 
0.54–1.06) (Table 2). Although the association of high number of menstrual cycles was non-
significant, in the subset of never-smokers the pooled OR was 0.68 (95%CI 0.60–0.91) 
(Table 2). An elevated but non-significant OR was observed in women with later menopause 
(OR≥55vs≤39 1.32, 95%CI 0.93–1.87) (P trend=0.63). Number of pregnancies, number of 
births and age at first birth showed no associations with PC risk (Table 2). We also evaluated 
a mutually adjusted model including all sources of hormone exposure: exogenous hormones, 
lifetime cumulative menstrual cycles (as a summary variable for endogenous hormone 
exposure); and gynecological surgery: hysterectomy and oophorectomy. Since not all the 
studies collected all the information mentioned previously, two separate models were 
analyzed. Studies that contributed significantly to heterogeneity in the pooled estimates in 
table 2 were excluded for the mutually adjusted model. The first model included lifetime 
cumulative menstrual cycles, HRT and OC use; the studies that provided information were 
MSKCC, Central Europe and Shanghai-II. A non-significant pooled OR below unity was 
observed in women with more than 455 cycles compared with women with at most 333 
cycles (OR>455vs≤333 0.75, 95%CI 0.51–1.12); the pooled OR for HRT users was 0.87 
(95%CI 0.55–1.24). A null effect was observed for OC users (Model 1; Table 3). The second 
mutually adjusted model included MDACC, MSKCC, Toronto, UCSF, Central Europe and 
SEARCH studies. For this model, the joint effect of hysterectomy and HRT use was 
evaluated according to the following categories: use of neither, HRT use alone, hysterectomy 
alone, and both hysterectomy plus HRT use (Model 2; Table 3). This joint effect variable 
was evaluated because the frequency of HRT use was three times as high in women who had 
had hysterectomies than not (data not shown). History of oophorectomy and OC use were 
also included in the model (Model 2; Table 3). The joint effect analysis of hysterectomy and 
HRT use showed that HRT use without hysterectomy conveyed a non-significant inverse 
association with PC (ORHRTvsnone 0.84, 95%CI 0.64–1.10), while a significant inverse 
association with PC risk was observed in women with hysterectomy without HRT use 
(ORhysterectomyvsnone 0.70, 95%CI 0.54–0.92) which was somewhat lower 
(ORhysterectomy+HRTvsneither 0.64, 95%CI 0.48–0.84) for women also taking HRT. No 
statistically significant association was observed in relation to oophorectomy. A sensitivity 
analysis was performed, where the joint effect was considered only when HRT use started at 
the same time or after the hysterectomy, however, the results did not change (data not 
shown). A forest plot of the study-specific and the pooled ORs for the joint effect of 
hysterectomy and use of HRT and PC risk is presented in Figure 1.
We found no evidence for effect-measure modification of the relation between each factor 
and PC risk by cigarette smoking, BMI, and history of diabetes (all likelihood ratio statistic 
p-values>0.05) (data not shown). Sensitivity analyses in never-smoking women and in 
postmenopausal women were performed, but in general, except as noted above, results did 
not change (Table 2 and 3). No major differences in pooled OR estimates were observed 
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when proxy-respondents were excluded from the mutually adjusted models or when models 
were stratified by the source of control participants (data not shown).
DISCUSSION
The present pooled data analysis of eleven case-control studies, including 2,838 pancreatic 
cancer case women and 4,748 controls, allowed us to estimate more precisely possible 
relations between menstrual and reproductive factors, hormone use, and PC risk. Our results 
suggest that undergoing hysterectomy may significantly reduce the risk of developing PC by 
22%.
A non-statistically significant OR below unity was observed with high lifetime cumulative 
number of menstrual cycles (>455 cycles). When the analysis was restricted to never-
smokers, this association became statistically significant. Lifetime cumulative menstrual 
cycles is an index for total exposure to endogenous hormones. Since hormonal levels differ 
during pregnancy, we subtracted from the calculation 36 and 12 weeks for each birth and 
abortion, respectively, and included the number of pregnancies as an adjustment variable; 
and hormone use (HRT and OC) was also included in the model. Chavez-MacGregor27 also 
excluded from the calculation a 6-week absence of cycles for women who reported lactation, 
and they accounted for menstrual cycle irregularity. Unfortunately, this information was not 
available in the included PanC4 studies. Because smoking is an important risk factor for PC 
and may also affect sex hormone levels32, we carried out additional analyses limited to 
never-smokers, though similar patterns of relative risk were observed. Obese and overweight 
persons have an increased risk of PC33, and high BMI is positively associated with high 
estrogens levels34, but in our analysis, different levels of BMI did not alter our OR 
estimations. Further analyses were also performed in postmenopausal women, and similar 
estimates of risk and 95%CIs were observed.
In the published literature, seven previous studies of PC collected information on 
oophorectomy and hysterectomy; and all case-control studies that collected this 
information18–20,35 were included in the present pooled analysis. Hysterectomy prevalence 
in PanC4 cases is almost 28% (American studies: 33%, European studies: 21%). In the 
American cohort studies hysterectomy prevalence in PC cases is approximately 40%36,37, 
while in the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort the 
prevalence was almost 15%38. The Iowa Women's health study (IWHS) cohort showed a 
statistically significant increase in risk for both hysterectomy (hazard ratio (HR): 1.37, 
95%CI: 1.02–1.82) and bilateral oophorectomy (HR: 1.43, 95%CI: 1.01–2.00)39. The EPIC 
cohort observed a no effect of bilateral oophorectomy and hysterectomy with ovarian 
conservation on PC risk38. The Cancer Prevention Study-II Nutrition Cohort found that 
hysterectomy with ovarian conservation was associated with an increased risk of PC (OR 
1.48, 95%CI 1.03–2.14), although no effect of hysterectomy with bilateral oophorectomy on 
PC was observed (OR 0.97, 95%CI 0.69–1.37)36. A recent meta-analysis observed16 an 
inverse association in relation to hysterectomy and PC risk in case-control studies (OR 0.77, 
95%CI 0.64–0.94) and no association in cohort studies. This result in case-control studies 
agreed with our general findings on hysterectomy (OR 0.78, 95%CI 0.67–0.91). 
Discrepancies between cohort studies and case-controls studies might be explained by 
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selection bias in hospital-based (HB) case-control studies, however, we observed that the 
association between hysterectomy and PC was borderline in the population-based (PB) case-
control studies (PB: OR: 0.84, 95%CI 0.69–1.01; HB: OR: 0.70, 95%CI 0.54–0.90) and 
results by source of controls were not considered heterogeneous (Wald statistic for 
heterogeneity: 1.21, p-value=0.271).
The role of HRT in relation to PC risk is not clear. While two cohort37,40 showed non-
significant inverse associations, one cohort study41 and a case-control studies42 showed non-
significant increases in risk. Finally, two studies showed relative risk estimates for HRT 
close to unity38,39. All remaining case-control studies were included in our pooled 
analysis18–20,35. None of these studies, or our pooled analyses, were able to distinguish the 
type of hormone therapy used, for example, whether combinations of estrogen and progestin 
were used, or estrogen alone. Use patterns for type of hormone therapy have changed over 
the past decades, with eras of estrogen alone and estrogen plus progestin43. The Women’s 
Health Initiative (WHI) randomized controlled trial findings support the hypothesis that 
estrogen alone or estrogen plus progestin may not have the same biological effects. The 
WHI observed that women who reported the combination of estrogen and progestin had an 
increased risk of breast cancer and a non-significant decrease in the risk of endometrial 
cancer44; while taking estrogen alone did not show an increase of breast cancer in women 
with hysterectomy45. Thus, estrogen-only HRT is usually recommended for women who 
have had hysterectomy43. To evaluate the influence of changes in the consumption patterns 
of HRT, we analyzed the use of HRT by study year (before 2002 vs. after 2002); and we 
observed no differences in the pooled risk estimate.
In PanC4, information on HRT type was not available; however, we did observe that the 
frequency of HRT use was three times as high among women who reported hysterectomy 
than not. Further, almost 57% of women started the HRT treatment at the age of the 
hysterectomy, and 30% after hysterectomy. We observed a 36% lower risk in comparison to 
women with intact uteri and who had not used HRT. It is possible that women who have had 
hysterectomy and used HRT may have lower PC risk because of other factors besides 
hysterectomy and HRT.
Some diseases, for which the treatment is hysterectomy, are directly related with increased 
female hormone levels. Almost 70% of American women46 during their fertile life will have 
fibroids. In many cases, fibroids do not cause symptoms, however, they can cause abnormal 
bleeding, and pelvic pressure, for which hysterectomy is the recommended treatment46,47. 
Among the factors that can contribute to fibroid growth are elevated levels of estrogens and 
progesterone47. Further, women diagnosed with hyperplasia tend to undergo hysterectomy 
surgery48. Hyperplasia is associated with higher levels of estrogens and insufficient levels of 
progesterone, and may evolve to endometrial cancer48. Unfortunately, the specific reason for 
having a hysterectomy was not available in PanC4 data, so we could not verify if the 
observed protective effect that was shown with hysterectomy was due to underlying elevated 
estrogen levels in the mentioned diseases or to other factors related to having a 
hysterectomy.
Lujan-Barroso et al. Page 8













Lifetime cumulative menstrual cycles is an index that attempts to summarize reproductive 
information, including information on menarche, menopause, pregnancies, OC and lactation. 
Our analytical approach allowed us to evaluate the index including these factors, with the 
exception of lactation. Three previous studies of pancreatic cancer have evaluated the index, 
but each study used a different calculation and different adjustment variables38,39,49. All the 
studies, including our analysis, found no association between lifetime cumulative menstrual 
cycles and PC risk, suggesting little or no effect of female hormones on PC risk.
In light of the inconsistent results between the studies on menstrual and reproductive factors, 
hormone use and PC risk, it is worth noting that previous studies had diverse study designs, 
target populations and confounder and adjustment variables; specifically, adjustments for 
smoking and alcohol. Furthermore, risk estimates for hysterectomy and for oophorectomy 
were inconsistent in our analysis with those provided by cohort studies36,38,39, possibly 
caused by selection bias in case-control studies.
The main weakness of our analysis is that not all of the studies collected all of the 
information on menstrual and reproductive factors and hormone use. Thus, mutually 
adjusted models could be obtained in only 4 or 6 studies, depending on the included 
variables, and a model that contained all collected factors in all studies was not possible. 
Another weakness of our analyses is that for some variables such as age at menopause, and 
for OC and HRT durations, we received categorical variables from some of the studies, so 
cut points for these variables had to be based on the received information, or the information 
could not be included in the calculation of lifetime cumulative menstrual cycles. Also, time 
periods of studies varies from the 1980’s to 2011, however, low heterogeneity between 
studies in each pooled OR estimation was observed. Even so, the PanC4 consortium includes 
a large dataset which allowed us to adjust for cigarette smoking, alcohol intake, and other 
potential confounding variables, and with sufficient power to estimate ORs across strata of 
major PC risk factors, for example, smoking, BMI, and diabetes.
In conclusion, our pooled analysis found no associations between age at menarche, 
menopause, lifetime cumulative menstrual cycles, oophorectomy, parity, history of OC use, 
and PC risk, but suggests that women who have had hysterectomy may be at lower risk of 
PC. Further investigations by type and formulation of HRT and reason for hysterectomy 
could clarify the role, if any, of hysterectomy in relation to PC risk.
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Study-specific and pooled OR estimates for the associations of hysterectomy and HRT use 
with risk of PC in PanC4 women (Model 2; Table 3)
Footnote for figure 1: Adjusted for: age in 5-year categories, education, BMI, cigarette 
smoking, diabetes, alcohol, center, oophorectomy and OC use.
Box sizes are weighted by the inverse of the variance; HRT: hormone replace therapy; OC: 
oral contraceptive
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